Form 4: Tandem Diabetes Care Officer Shannon Hansen Reports Stock Transactions

Shannon Hansen, Chief Legal Officer of Tandem Diabetes Care, reports acquisition and disposal of company stock and derivative securities.

Summary

• On May 15, 2024, Shannon Hansen, Chief Legal Officer of Tandem Diabetes Care, reported transactions involving the company's stock.
• These transactions included the acquisition of 799 shares of common stock through the Employee Stock Purchase Plan at $15.64 per share.
• Hansen also acquired 531 shares and 5,748 shares through the vesting of restricted stock units (RSUs).
• A total of 190 shares and 2,051 shares were withheld by the company to cover tax obligations related to the vesting of RSUs at a price of $47.37.
• Following these transactions, Hansen directly owns 8,413 shares and indirectly owns 1,935 shares through the Shannon M. Hansen Trust.
• Hansen directly owns 3,715 restricted stock units from a 2022 award and 11,497 restricted stock units from a 2023 award.

Sentiment

Score: 5

Explanation: The document is a neutral report of stock transactions, with no inherent positive or negative sentiment.

Positives

• The acquisition of shares through the Employee Stock Purchase Plan indicates Hansen's investment in the company's future.
• The vesting of RSUs is a form of compensation that aligns Hansen's interests with the company's performance.

Negatives

• Shares were withheld to cover tax obligations, reducing the net increase in Hansen's holdings.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, which is common in publicly traded companies. It provides transparency into the actions of key personnel.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading.
• The transactions reported are typical for executives receiving stock-based compensation and participating in employee stock purchase plans.
• Similar filings can be observed for executives at comparable companies in the medical device industry, such as Medtronic or Abbott Laboratories.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly increasing the number of outstanding shares.
• Employees participating in the ESPP benefit from the opportunity to purchase company stock at a potentially discounted price.

Key Dates